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http://www.biomedcentral.com/1471-2350/15/60RESEARCH ARTICLE Open AccessApolipoprotein E gene ε4ε4 is associated with
elevated risk of primary open angle glaucoma in
Asians: a meta-analysis
Yong Wang, Yan-Feng Zhou, Bing-Ying Zhao, Zheng-Yu Gu and Shou-Ling Li*Abstract
Background: Epidemiological studies have evaluated the association between Apolipoprotein E (APOE) gene ε2/ε3/ε4
polymorphism and glaucoma susceptibility. However, the published data are still inconclusive. The aim of the present
study is to evaluate the impact of APOE gene ε2/ε3/ε4 polymorphism on glaucoma risk by using meta-analysis.
Methods: A comprehensive literature search of PubMed, EMBASE, Cochrane, Elsevier Science Direct and CNKI databases
was conducted to identify relevant articles, with the last report up to January 5, 2014. Pooled odds ratio (OR) and 95%
confidence interval (CI) were used to assess the strength of association by using the fixed or random effect model.
Results: Fifteen separate studies including 2,700 cases and 2,365 controls were included in the meta-analysis. We did
not detect a significant association between APOE gene ε2/ε3/ε4 polymorphism and glaucoma in overall population
(P > 0.0083). In Asians, we detected an association of the ε4ε4 genotype with elevated risk for glaucoma (OR = 5.22,
95% CI = 1.85-14.68, P = 0.002), mainly for primary open angle glaucoma (OR = 4.98, 95% CI = 1.75-14.20, P = 0.003).
Conclusions: The meta-analysis suggests that APOE gene ε4ε4 may be associated with elevated risk for primary open
angle glaucoma in Asians. However, more epidemiologic studies based on larger sample size, case–control design and
stratified by ethnicity as well as types of glaucoma are suggested to further clarify the relationship between APOE gene
ε2/ε3/ε4 polymorphism and genetic predisposition to glaucoma.
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Glaucoma, a group of diseases causing optic neuropathy,
is characterized by optic nerve head changes and visual
field loss, and is the second leading cause of irreversible
blindness across the world [1,2]. In 1995, the World Health
Organization reported that 5.1 million people were
bilaterally blind from glaucoma [1]. Glaucoma is expected
to affect 79.6 million people worldwide by the year 2020
[2]. Its morbidity and prevalence make it a significant pub-
lic health problem [1]. However, to date, the pathogenesis
of glaucoma remains largely unknown, with both genetic
and environmental factors contributing to the pathophysi-
ology [1,3]. Over the last decade, the application of molecu-
lar genetic techniques to the study of glaucoma has
been accelerated greatly, and the accumulating evidence* Correspondence: shouling_li@163.com
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unless otherwise stated.supports an important role for genetics in determining
risk for this disease [3].
Apolipoprotein E (APOE), which is a major apolipo-
protein in the central nervous system, plays an import-
ant role in the uptake and redistribution of cholesterol
within neuronal network [4]. APOE gene is located on
human chromosome 19q13.2 and is polymorphic [5,6].
There are three common APOE isoforms E2, E3 and
E4, encoded by different alleles (ε2, ε3 and ε4), which
vary significantly in structure and functions [7]. APOE
gene ε2/ε3/ε4 polymorphism has been associated with
several neurodegenerative diseases such as Alzheimer's
and Parkinson's diseases [8,9]. Therefore, it is possible
that this polymorphism may be associated with glau-
coma risk [10]. Recently, a number of studies have
been conducted to investigate the association of APOE
gene ε2/ε3/ε4 polymorphism with glaucoma risk [11-25].
However, the results are controversial with some reportstd. This is an Open Access article distributed under the terms of the Creative
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others showed no association [11,12,14,16,17,22,23]. The
inconsistent conclusion may be due to the relatively
small size of subjects, since small sample sized association
studies could be very limited for efficient assessment of
the association.
Integration of these studies may provide improved
statistical power to detect the significance. Meta-analysis
is a statistical procedure for combining the results of
several studies to produce a single estimate of the major
effect with enhanced precision [26]. Recently, two studies
assessed the association of APOE gene ε2/ε3/ε4 polymorph-
ism with primary open angle glaucoma (POAG) by using
meta-analysis [27,28]. Their meta-analyses suggest that this
polymorphism is not associated with POAG susceptibility.
However, the results of their meta-analyses should be
interpreted with caution due to some potential limitations.
Therefore, in this study, we conducted a meta-analysis
to derive a more precise estimation of the association
between APOE gene ε2/ε3/ε4 polymorphism and the
risk for glaucoma.
Methods
Search strategy and inclusion criteria
This meta-analysis was reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) Statement, issued in 2009
(Additional file 1: Table S1). Electronic databases, including
PubMed, Excerpta Medica Database (EMBASE), Cochrane,
Elsevier Science Direct and China National Knowledge
Infrastructure (CNKI) databases, were searched for identi-
fication of the studies on APOE gene polymorphisms and
glaucoma published up to January 5, 2014. Search terms
included ‘glaucoma’ and ‘apolipoprotein OR APOE OR
Apo E OR ApoE’. There was no language restriction.
Review articles and original papers were searched by
hand for additional eligible studies. The following criteria
were used to select the eligible studies: (a) evaluation of the
association between APOE gene ε2/ε3/ε4 polymorphism
and glaucoma risk; (b) an unrelated case–control study
in which family members were excluded; (c) sufficient
published data for estimating an odds ratio (OR) with
95% confidence interval (CI). When authors reported
two or more publications on the same patient population,
only the largest study was selected. Additionally, when a
study reported the results on different subpopulations, we
treated them as a separate study.
Data extraction
Information was carefully extracted from all eligible publi-
cations independently by two investigators. Disagreement
was resolved by discussion between the two investigators.
The following data were collected from each study: the
first author’s name, publication year, source of publication,ethnicity, sample size (numbers of cases and controls),
types of glaucoma, and allele as well as genotype fre-
quencies. Authors were contacted for further informa-
tion when necessary.
Statistical analysis
Pooled OR with 95% CI was used to assess the strength
of association between APOE gene ε2/ε3/ε4 polymorph-
ism and glaucoma risk. The significance of the pooled
OR was determined by Z test. Genotype ε3ε3 is the most
common genotype [29]. Thus, genotype ε3ε3 or allele ε3
is designated as reference category in the present study.
We estimated the risk of the ε2 and ε4 alleles, compared
with the ε3 allele. We also performed genotypic analyses
(ε2 carriers versus ε3ε3, ε2ε2 versus ε3ε3, ε4 carriers ver-
sus ε3ε3 and ε4ε4 versus ε3ε3). ε2 carriers were defined
as patients with the ε2ε2 and ε2/ε3 genotypes. ε4 carriers
were defined as patients with the ε3ε4 and ε4ε4 geno-
types. Genotype ε2ε4 was excluded from the genotypic
analyses because of the opposite effect between ε2 and
ε4 alleles [15,30]. In addition, we performed subgroup
analyses by ethnicity (Cauasians and Asians) and types
of glaucoma (POAG) when the data were available.
Subgroup analyses were also performed by excluding
those studies which did not fulfill Hardy-Weinberg
equilibrium (HWE). We carried out sensitivity analysis
by excluding one study at a time to explore whether the
results were influenced by a specific study. Heterogeneity
(between-study inconsistency) was investigated and mea-
sured using Cochran’s Q statistic and I2 statistic [31,32]. A
P value greater than 0.10 indicated a lack of heterogeneity
among studies, so the fixed effect model (Mantel-Haenszel
method) was used to calculate pooled OR [33]. Otherwise,
the random effect model (DerSimonian-Laird method)
was used [34]. Publication bias was detected using Egger’s
linear regression test by visual inspection of funnel plot
[35]. A Chi square-test was used to evaluate the deviation
from HWE in controls. All analyses were done with the
software Review Manager (v4.2; Oxford, England) and Stata
statistical software (v10.0; StataCorp, College Station, TX,
USA), using two-sided P values. P values were Bonferroni
adjusted to account for multiple testing. In overall analyses,
P values below 0.0083 (0.05/6) were considered statisti-
cally significant, and, in subgroup analyses, P values below
0.0042 (0.05/12) were considered statistically significant.
Results
Characteristics of studies
Characteristics of studies investigating the association of
APOE gene ε2/ε3/ε4 polymorphism with glaucoma risk
are presented in Table 1 [11-24]. The study selection
process is shown in Figure 1. There were 666 articles
relevant to the searching terms (PubMed: 51; EMBASE:
95; Cochrane: 0; Elsevier Science Direct: 513; CNKI: 7).








Number of cases Number of controls HWE
P-valueε2 ε3 ε4 ε2 ε3 ε4
Krumbiegel 2010 [11] Caucasian (German) 801(459/342) PEXG 79 740 99 51 547 86 0.926
Krumbiegel 2010 [11] Caucasian (Italian) 323(133/190) PEXG 21 222 23 23 317 40 0.024
Saglar 2009 [12] Caucasian 194(75/119) POAG 13 126 11 10 204 24 0.832
Al-Dabbagh 2009 [13] Asian 230(100/130) POAG,PACG 0 181 19 0 249 11 0.969
Jia 2009 [14] Asian 376(176/200) POAG 34 278 40 35 329 36 0.897
Yuan 2007 [15] Asian 162(105/57) POAG,PACG 48 81 81 18 76 20 <0.0001
Zetterberg 2007 [16] Caucasian 429(242/187) POAG 50 376 58 42 289 43 0.923
Hu 2007 [17] Asian 219(142/77) POAG 17 229 38 11 129 14 0.409
Tamura 2006 [18] Asian 105(28/77) POAG 3 42 11 12 135 7 0.079
Lam 2006 [19] Asian 700(400/300) POAG 79 674 47 50 495 55 0.065
Mabuchi 2005 [20] Asian 489(310/179) POAG 16 567 37 18 302 38 0.104
Jünemann 2004 [21] Caucasian 128(96/32) POAG 19 146 27 9 40 15 0.012
Lake 2004 [22] Caucasian 504(155/349) POAG 28 229 53 56 534 108 0.316
Ressiniotis 2004 [23] Caucasian 212(137/75) POAG 35 199 40 16 114 20 NA#
Vickers 2002 [24] Caucasian 193(142/51) POAG 27 206 51 15 75 12 0.202
*HWE: Hardy-Weinberg equilibrium; PEXG: pseudoexfoliation glaucoma; POAG: primary open angle glaucoma; PACG: primary angle closure glaucoma; NA: not
available. #Only allele frequency was extracted from the study.
Figure 1 Flow diagram of the study selection process.
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gene polymorphisms and glaucoma. Three studies did not
explore the ε2/ε3/ε4 polymorphism and were excluded
[36-38]. One study was excluded due to duplicate report
[39], and another study was excluded due to unavailable
data [25]. Krumbiegel et al. [11] provided data on two dif-
ferent subpopulations (German and Italian), and, thus, each
subpopulation was treated as a separate study. Finally, a total
of fifteen separate studies including 2,700 cases and 2,365
controls were included in the present meta-analysis [11-24].
The allele and genotype frequencies of APOE gene
ε2/ε3/ε4 polymorphism were extracted from fourteen
separate studies [11-22,24]. Only allele frequency was
extracted from the study by Ressiniotis et al. [23]. The
results of HWE test for the distribution of the genotype
in control population are shown in Table 1. The genotype
distributions in eleven separate studies were in agreement
with HWE. The genotype distributions in 3 separate stud-
ies were not in agreement with HWE. It was unavailable
for the study by Ressiniotis et al. to perform HWE test.
The fifteen studies consisted of eight Caucasian studies
and seven Asian studies. Of these studies, two studies
were conducted in patients with pseudoexfoliation
glaucoma (PEXG), eleven studies were conducted in
patients with primary open angle glaucoma (POAG),
and two studies were conducted in patients with POAG
and primary angle closure glaucoma (PACG).
Quantitative synthesis
The results of the meta-analysis on the association between
APOE gene ε2/ε3/ε4 polymorphism and risk of glaucoma
are shown in Table 2. By pooling all the studies, APOE gene
ε2/ε3/ε4 polymorphism was not associated with glaucoma
risk (P > 0.0083). We detected significant between-study
heterogeneity for the contrasts of ε2 versus ε3, ε2 carriers
versus ε3ε3, ε4 versus ε3 and ε4 carriers versus ε3ε3 in
overall population (P < 0.1). We carried out subgroup ana-
lyses by excluding those studies which did not fulfill HWE,
and found similar results (P > 0.0042). Significant between-
study heterogeneity for the contrasts of ε2 carriers versus
ε3ε3, ε4 versus ε3 and ε4 carriers versus ε3ε3 was detected
in HWE population (P < 0.1).
When stratified by ethnicity, no association was
found between APOE gene ε2/ε3/ε4 polymorphism and
risk of glaucoma in Caucasians (P > 0.0042). No signifi-
cant between-study heterogeneity was found in Caucasians
(P > 0.1). In Asians, we detected an association of the ε4ε4
genotype with elevated risk for glaucoma (OR = 5.22, 95%
CI = 1.85-14.68, P = 0.002). But we did not find signifi-
cant association of APOE gene ε2/ε3/ε4 polymorphism
with glaucoma in other models (P > 0.0042). Significant
between-study heterogeneity was found for the contrasts
of ε2 versus ε3, ε2 carriers versus ε3ε3, ε4 versus ε3 and ε4
carriers versus ε3ε3 in Asians (P < 0.1).In subgroup analysis by types of glaucoma, we also de-
tected an association of the ε4ε4 genotype with elevated
risk for POAG in Asians (OR = 4.98, 95% CI = 1.75-14.20,
P = 0.003), but not for POAG in Caucasians (P > 0.0042). In
POAG population (Asians), we detected significant between-
study heterogeneity for the contrasts of ε2 carriers versus
ε3ε3, ε4 versus ε3 and ε4 carriers versus ε3ε3 (P < 0.1).
Potential publication bias and sensitivity analysis
For most of comparisons, the shapes of the funnel plots
did not reveal any evidence of obvious asymmetry (funnel
plots not shown), and these results were further supported
by analysis via Egger’s linear regression test (Table 3). We
only found publication bias for the contrasts of ε4 carriers
versus ε3ε3 in overall population and HWE population, ε4
versus ε3 as well as ε4 carriers versus ε3ε3 in Asians and
POAG (Asians) subgroup (P < 0.05). Additionally, Egger’s
test was not applied in the contrast of ε2ε2 versus ε3ε3 in
Asians and the contrasts of ε2ε2 versus ε3ε3 as well as ε4
carriers versus ε3ε3 in POAG (Asians) subgroup due to
the rare frequency of homozygous mutation.
We carried out sensitivity analysis by excluding one
study at a time to explore whether the positve result of
POAG (Asians) subgroup were influenced by a specific
study. Sensitivity analysis indicated that a significant
variation in combined ORs by excluding the study by
Al-Dabbagh et al. (OR = 4.01, 95% CI = 1.29-12.46, P = 0.02)
or the study by Yuan et al. (OR = 4.04, 95% CI = 1.30-12.50,
P = 0.02) or the study by Tamura et al. (OR = 4.62, 95%
CI = 1.54-13.90, P = 0.006).
Discussion
Recently, two studies assessed the association of APOE
gene ε2/ε3/ε4 polymorphism with POAG by using meta-
analysis [27,28]. Their meta-analyses suggest that this
polymorphism is not associated with POAG susceptibil-
ity. However, the results of their meta-analyses should
be interpreted with caution due to some limitations. In
the study by Song et al. [27], the authors did not include
all available published studies. Five eligible studies were
not include in the meta-analysis [13,15,17,21,23]. Mean-
while, two studies contained overlapping data [19,39],
and only the largest study [19] should be selected for the
analysis. In another study by Wang et al. [28], there were
many mistakes in the data extraction (see Supplementary
Table two in their article). For example, the authors con-
fused the cases and controls for the study by Zetterberg
et al. [16]. The data provided by the authors for the study
by Vickers et al. [24] were not in line with the data provided
by Vickers et al. in their original publication. Close inspec-
tion of the data in the study by Jia et al. [14] revealed that
the number of the ε2, ε3 and ε4 alleles in cases should be
34, 278 and 40, but not 34, 280 and 38 in the study by
Wang et al.. These limitations distorted the results of their
Table 2 Meta-analysis of the association between apolipoprotein E gene ε2/ε3/ε4 polymorphism and glaucoma*
Groups Sample size Number of
Studies
Test of association Test of heterogeneity
Case Control OR (95% CI) Z P-value Model χ2 P-value I2(%)
Overall ε2 vs ε3 4765 4201 15 1.08(0.88-1.32) 0.74 0.46 R 20.83 0.08 37.6
ε2 carriers vs ε3ε3 2001 1804 14 1.02(0.79-1.33) 0.18 0.86 R 21.18 0.05 43.3
ε2ε2 vs ε3ε3 1688 1541 14 1.11(0.54-2.28) 0.28 0.78 F 3.51 0.83 0.0
ε4 vs ε3 4931 4364 15 1.14(0.86-1.51) 0.92 0.36 R 58.45 <0.0001 76.0
ε4 carriers vs ε3ε3 2146 1955 14 1.15(0.82-1.59) 0.81 0.42 R 50.80 <0.0001 74.4
ε4ε4 vs ε3ε3 1704 1549 14 1.66(0.99-2.78) 1.92 0.05 F 14.05 0.23 21.7
Controls in HWE ε2 vs ε3 3994 3588 11 1.03(0.87-1.22) 0.36 0.72 F 11.02 0.27 18.3
ε2 carriers vs ε3ε3 1790 1597 11 0.93(0.71-1.22) 0.54 0.59 R 15.50 0.08 41.9
ε2ε2 vs ε3ε3 1525 1359 11 1.34(0.62-2.90) 0.73 0.46 F 2.05 0.92 0.0
ε4 vs ε3 4112 3722 11 1.10(0.83-1.47) 0.69 0.49 R 33.90 0.0002 70.5
ε4 carriers vs ε3ε3 1900 1723 11 1.04(0.77-1.42) 0.26 0.79 R 29.86 0.0009 66.5
ε4ε4 vs ε3ε3 1533 1367 11 1.41(0.80-2.50) 1.18 0.24 F 10.35 0.32 13.1
Caucasian ε2 vs ε3 2516 2342 8 1.08(0.89-1.31) 0.74 0.46 F 7.70 0.36 9.1
ε2 carriers vs ε3ε3 996 963 7 1.07(0.84-1.36) 0.55 0.58 F 6.65 0.35 9.8
ε2ε2 vs ε3ε3 821 813 7 0.92(0.41-2.09) 0.20 0.84 F 2.74 0.60 0.0
ε4 vs ε3 2606 2468 8 0.96(0.81-1.13) 0.51 0.61 F 7.89 0.34 11.3
ε4 carriers vs ε3ε3 1079 1076 7 0.93(0.75-1.14) 0.73 0.46 F 4.62 0.59 0.0
ε4ε4 vs ε3ε3 823 822 7 0.92(0.47-1.77) 0.26 0.79 F 5.52 0.36 9.3
Asian ε2 vs ε3 2249 1859 7 1.07(0.71-1.62) 0.32 0.75 R 13.05 0.02 61.7
ε2 carriers vs ε3ε3 1005 841 7 0.95(0.56-1.63) 0.18 0.86 R 14.41 0.01 65.3
ε2ε2 vs ε3ε3 867 728 7 2.08(0.45-9.63) 0.94 0.35 F 0.04 0.98 0.0
ε4 vs ε3 2325 1896 7 1.53(0.83-2.84) 1.36 0.17 R 48.44 <0.0001 87.6
ε4 carriers vs ε3ε3 1067 879 7 1.56(0.77-3.13) 1.24 0.21 R 45.75 <0.0001 86.9
ε4ε4 vs ε3ε3 881 727 7 5.22(1.85-14.68) 3.13 0.002 F 2.95 0.71 0.0
POAG (Caucasian) ε2 vs ε3 1454 1404 6 1.02(0.80-1.30) 0.13 0.90 F 6.95 0.22 28.1
ε2 carriers vs ε3ε3 522 549 5 0.99(0.72-1.37) 0.05 0.96 F 5.92 0.20 32.5
ε2ε2 vs ε3ε3 426 457 5 0.79(0.26-2.44) 0.41 0.68 F 0.56 0.76 0.0
ε4 vs ε3 1522 1478 5 1.04(0.84-1.28) 0.34 0.74 F 6.56 0.26 23.8
ε4 carriers vs ε3ε3 581 613 5 1.01(0.76-1.33) 0.05 0.96 F 3.59 0.47 0.0
ε4ε4 vs ε3ε3 430 463 5 1.24(0.55-2.77) 0.52 0.60 F 3.05 0.38 1.6
POAG (Asian) ε2 vs ε3 2091 1859 7 0.96(0.75-1.22) 0.34 0.73 F 6.27 0.28 20.2
ε2 carriers vs ε3ε3 953 841 7 0.78(0.48-1.27) 1.00 0.32 R 10.68 0.06 53.2
ε2ε2 vs ε3ε3 827 728 7 2.08(0.45-9.63) 0.94 0.35 F 0.04 0.98 0.0
ε4 vs ε3 2149 1896 7 1.45(0.82-2.55) 1.29 0.20 R 37.92 <0.0001 84.2
ε4 carriers vs ε3ε3 1000 879 7 1.45(0.76-2.76) 1.13 0.26 R 36.86 <0.0001 83.7
ε4ε4 vs ε3ε3 838 727 7 4.98(1.75-14.20) 3.01 0.003 F 3.01 0.70 0.0
*POAG: primary open angle glaucoma; HWE: Hardy-Weinberg equilibrium; vs: versus; OR: odds ratio; CI: confidence interval; F: fixed effect model; R: random
effect model.
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reviewed all available published studies and performed a
meta-analysis to derive a more precise estimation of the as-
sociation between APOE gene ε2/ε3/ε4 polymorphism and
susceptibility to glaucoma. Our meta-analysis included fif-
teen separate studies involving 2,700 cases and 2,365controls. In Asians, we detected an association of the ε4ε4
genotype with elevated risk for glaucoma, mainly for
POAG. Thus, the ε4ε4 genotype may be associated with el-
evated risk for POAG in Asians.
Glaucoma is a term describing a group of ocular disor-
ders with multi-factorial etiology united by a clinically
Table 3 Egger’s linear regression test to measure the funnel plot asymmetry*
Groups Y axle intercept: a (95% CI)
Overall Controls in HWE Caucasian Asian POAG (Caucasian) POAG (Asian)
ε2 vs ε3 −0.66(−3.09-1.77) −0.93(−3.39-1.54) −0.22(−3.69-3.23) −1.06(−6.79-4.66) 0.03(−5.81-5.87) −1.68(−4.48-1.13)
ε2 carriers vs ε3ε3 −0.03(−2.36-2.29) −1.38(−4.14-1.38) 0.55(−2.73-3.83) −0.50(−5.90-4.90) 1.14(−4.80-7.08) −2.07(−7.60-3.46)
ε2ε2 vs ε3ε3 −0.94(−5.04-3.15) −0.94(−5.04-3.15) −3.15(−8.03-1.73) NA −2.28(−16.07-11.52) NA
ε4 vs ε3 2.81(−0.76-6.39) 3.21(−0.14-6.56) −0.45(−3.63-2.73) 7.63(0.14-15.12) −1.60(−6.29-3.08) 7.26(2.85-11.66)
ε4 carriers vs ε3ε3 3.49(0.56-6.41) 3.23(0.16-6.31) 0.38(−2.34-3.11) 7.73(3.29-12.18) 0.35(−4.70-5.40) 6.54(3.07-10.01)
ε4ε4 vs ε3ε3 −2.15(−5.52-1.22) −2.18(−6.29-1.93) −2.35(−6.03-1.32) 2.01(−1.14-5.15) −2.26(−6.69-2.17) NA
*POAG: primary open angle glaucoma; HWE: Hardy-Weinberg equilibrium; vs: versus; CI: confidence interval; NA: not available.
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opathy [1,40]. This disease often goes undetected. In the
United States, glaucoma is responsible for 9-12% of blind-
ness, and impacts up to three million Americans, but only
half of those are aware they have it [41]. Glaucoma is a
neurodegenerative disease, which is often associated
with high intraocular pressure [10,42]. In this disease,
there are cell bodies (retinal ganglion cells) and nerve
fibers (optic nerve axons) that are vulnerable to degen-
eration and amenable to protection. Neurodegeneration
occurs in the retinal ganglion neuronal cell bodies, their
axons in the optic nerve, the lateral geniculate nucleus,
optic radiation, and visual cortex [43,44]. APOE plays a
key role in lipid metabolism, cholesterol transport, as
well as protein synthesis, and is also involved in numer-
ous other functions, including tissue repair, cell growth
and differentiation, and immune response and regula-
tion [4,45]. APOE gene ε2/ε3/ε4 polymorphism has been
associated with a number of neurodegenerative diseases
such as Alzheimer's and Parkinson's diseases [8,9], rais-
ing the possibility that this polymorphism might predis-
pose to neurodegeneration of the retinal ganglion cells
and the optic nerve axons in glaucoma. In the study, we
found that the ε4ε4 genotype is associated with elevated
risk for POAG in Asians. The extracellular accumulation
of insoluble fibrillar peptides in brain parenchyma and
vessel walls as amyloid is the hallmark of neurodegenera-
tive diseases [46]. Amyloid β-peptide (Aβ) deposition in
senile plaques and cerebral vessels is a neuropathological
feature of Alzheimer’s disease [47]. There is evidence that
the amount of histologically identified Aβ in vessels and
plaques in the cerebral cortex of patients with Alzheimer’s
disease is a direct function of their APOE genotype,
and subjects with ε4ε4 genotype have an increased
amyloid deposits in vessels and density of strongly Aβ-
immunoreactive plaques than those with ε3ε3 genotype
[47]. Numerous similarities exist between glaucoma and
Alzheimer's diseases [10], and, thus, the evidence supports
our results. However, the exact function of APOE gene
ε2/ε3/ε4 polymorphism remains largely unknown, and
studies of the functional implications of this polymorphism
are still needed in the future. Additionally, we found thatthe ε4ε4 genotype is associated with elevated risk for POAG
in Asians, but not in Caucasians, which indicated that the
genetic background of Asians and Caucasians is different.
Some limitations of this meta-analysis should be ac-
knowledged. A first consideration is that we found
publication bias for some contrasts. A second consideration
is that significant between-study heterogeneity was found
in some comparisons, which may be distorting the results
of meta-analysis. In the subgroup analysis by ethnicity,
the heterogeneity disappeared among Caucasians. The
heterogeneity may have resulted from differences in the
subjects’ genetic backgrounds. Additionally, different types
of glaucoma may contribute to the heterogeneity. But most
of studies did not provide glaucoma subtype information
(e.g., normal tension glaucoma or high tension glaucoma).
Third, though we detected an association of the ε4ε4
genotype with elevated risk for glaucoma (with POAG
and PCAG combined) in Asians, only two studies were
conducted in patients with PACG (109 patients). Thus,
further studies exploring the association between APOE
gene ε2/ε3/ε4 polymorphism and PACG risk are still
needed. Fourth, sensitivity analysis indicated that a
significant variation in combined ORs by excluding
some studies. Finally, our results are based on un-
adjusted estimates, which may be distorting the results
of meta-analysis. A more precise analysis stratified by
environmental factors could be performed if individual
data were available.
Conclusions
In summary, the present meta-analysis suggests that APOE
gene ε4ε4 may be associated with elevated risk for POAG
in Asians. However, more epidemiologic studies based
on larger sample size, case–control design and stratified
by ethnicity as well as types of glaucoma are suggested to
further clarify the relationship between APOE gene ε2/ε3/ε4
polymorphism and genetic predisposition to glaucoma.Additional file
Additional file 1: Table S1. PRISMA Checklist.
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